Relevant Links
- Our very own discussion forum with patient support and personal updates, and a library of research and more! We have over 100 ASPS patients around the world, plus an additional 400 in China we can contact.
- An Article from the Liddy Shriver Sarcoma Initiative Website
- Journal article about ASPS history.
- Children’s Hospital Boston ASPS information page.
- A patient tells her ASPS story – Alicia Parlette’s blog.
- You can do your won research by reading peer reviewed literature. For example, here is a sample search on PUBMED.
- The Liddy Shriver Sarcoma Initiative undertakes activities that help improve the quality of life for people dealing with sarcoma.
Relevant Scientific Publications
Treatment options
- Value of repeat resections for survival in lung metastases from soft tissue sarcoma (Liebl et al. 2007)
- The new 1,318 nm Nd:YAG Laser system facilitates any kind of parenchymal lung resection in lobe sparing manner and in case of complete resection improves significantly the survival(Rolle et al. (1) 2006)
- Report: Surgeries for a total of 328 consecutive patients who had multiple lung metastases with a new 1318-nm Nd:YAG laser (Rolle et al. (2) 2006)
- Case studies of Alveolar Soft Part Sarcoma in MSKCC leads to the conclusion that practicing appropriate diagnostic techniques, aggressive surgical control of the primary tumor and long-term surveillance for metastases may result in long term survival (Kayton et al. 2006)
- Alveolar soft-part sarcoma responding to interferon alpha-2b (Roozendaal et al. 2003), case study.
- ASPS responds to intensive chemotherapy (Nickerson et al 2004), case study.
- Expression of Vascular Endothelial Growth Factor (VEGF) in ASPS and response to treatment with Avastin (bevacizumab) and interferon alpha-2b (Azizi et al. 2006), case study.
- ASPS Gene expression profiling of alveolar soft – part sarcoma (Stockwin et al 2009)
Potential ASPS Therapies
- TFE3 fusion gene activates MET signaling, indicating that ASPS is a target for therapeutic MET inhibition (Tsuda et al. 2007)
- Halofuginone for Alveolar Soft Part Sarcoma (Genin et al. 2008)
ASPS Clinical Studies
- Alveolar Soft Part Sarcoma: A Single-Center 26-Patient Case Series and Review of the Literature (Ogura et al. 2012)
- Alveolar Soft Part Sarcoma – An Italian Study (Casanova et al. 2000)
- Alveolar Soft Part Sarcoma – A Japanese Study (Ogose et al. 2003)
- Alveolar Soft Part Sarcoma – An American/ Texas Study (Portera et al. 2000)
The Genetics of Alveolar Soft Part Sarcoma
- The chromosomal translocation in Alveolar Soft Part Sarcoma creates fusion between two genes: ASPL-TFE3 (Ladanyi et al. 2001)
- ASPL-TFE3 fusion is involved in ASPS, but also in Renal Cancer (Argani et al. 2001)
- The translocation of ASPS occurs in G2 of the cell cycle (Huang et al. 2005)
Gene expression studies of ASPS tumors
- Staining of ASPL-TE3 in tumors of TFE3 fusions (Argani et al. 2003)
- Immunostaining of TFE3 as a tool in the diagnosis of Alveolar Soft Part Sarcoma (Miller, 2003)
- Angiogenesis – Promoting Gene Patterns in Alveolar Soft Part Sarcoma (Lazar et al. 2007)
- Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of Alveolar Soft Part Sarcoma (Vistica et al. 2008)
June 2006: The cancer inducing activity of the gene MITF is demonstrated in clear cell sarcoma
This finding suggests that MITF and possibly other MITF related genes: TFE3, TFEB and TFEC serve as “oncogene engines” to induce cancer formation. TFE3 is the translocated gene, which is found in alveolar soft part sarcoma. Click here to read a commentary in EurekAlert. The original study was published in the Cancer Cell journal: Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers